Scott Dehm
@scottdehm
Followers
984
Following
443
Media
23
Statuses
368
Professor @UMNcancer studying steroid hormones, androgen receptors, and #ProstateCancer genomes. Apogee Enterprises Chair in Cancer Research . Views=mine.
Minneapolis, MN
Joined May 2011
RT @JakeOrmeMDPhD: Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarak….
0
1
0
RT @LukeSelth: Check out our new work exploring AR biology in advanced prostate cancer: We found that tumours expr….
0
3
0
RT @ProstateCell: 🧪 Dr. @scottdehm and collaborators including @huang_lab, @EAntonarakis, & @mishabeltran showed that double-negative #CRPC….
0
2
0
@UMNCancer @UMN_GradSchool This study benefitted from tremendous collaborations with @huang_lab @EAntonarakis @mishabeltran @JoshLangMD @AttardLab and many others!.
0
0
2
This work was led by a talented graduate student (Sam Pitzen) @umncancer @UMN_GradSchool who will soon be defending his PhD thesis (and entering the job market).
1
0
4
KLF5 was identified as the transcription factor that supports these transcriptional features. Defining DNPC by what "it is" (a hybrid basal/club/hillock phenotype), instead of what "it's not" (negative for AR and neuroendocrine features) may aid development of new therapies.
1
0
3
We found that the double-negative phenotype of castration-resistant prostate cancer (a.k.a. "DNPC") exhibits the same transcriptional features that define basal, club, and hillock epithelial cells of the benign prostate.
1
0
1
Check out our latest study! Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer | PNAS
1
12
40
RT @JoshLangMD: Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis….
0
16
0
Excited to share a new paper by postdoc Dr. Kiel Tietz @UMNCancer! CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells: Cell Reports . Work funded by @CDMRP and @NCICancerBio.
2
6
26
RT @mishabeltran: In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss….
0
54
0
RT @EAntonarakis: The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Differ….
0
16
0
RT @DrChoueiri: PROSTATE Paper 2.Franseschini et al. developed a targeted DNA methylation assay for the detection of neuroendocrine prostat….
0
8
0
RT @DrChoueiri: It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY!. 1/ Prostate Paper 1.Fonseca et al. introdu….
0
77
0
RT @DrChoueiri: PROSTATE Paper 3.Knutson et al. developed the AR-ctDETECT assay to detect ctDNA in limiting plasma cfDNA from pts w/ #mCRPC….
0
11
0
RT @APCCC_Lugano: AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients out in….
0
14
0
@AarmstrongDuke @DukeCancer @DukeGUCancer @theNCI @PCFnews We thank all the contributors to this collaborative study! @UMNCancer @mishabeltran @charlesryanmd @EAntonarakis @lukegaughan22.
0
0
2
This study was a collaboration initiated with .@AarmstrongDuke and Susan Halabi .@DukeCancer @DukeGUCancer and was funded by .@theNCI and @PCFnews!.
1
0
8
Our paper out today in @NatureComms analyzed plasma from the phase 3 @ALLIANCE_org A031201 trial using the AR-ctDETECT assay. Patients positive for circulating tumor DNA had poor overall survival despite treatment with potent AR inhibitors.
6
14
59
RT @AarmstrongDuke: Susan Halabi representing @DukeGUCancer at #ASCO24 presenting our @ALLIANCE_org clinical genetic model using the @scott….
0
5
0